Breast cancer:
Indications for: Fluorouracil
Palliative management of carcinoma of the breast.
Adult Dosage:
Give by IV inj. 12mg/kg once daily for 4 successive days; max 800mg/day. If no toxicity is observed, 6mg/kg are given on the 6th, 8th, 10th, and 12th days unless toxicity occurs. Maintenance therapy: repeat dosage of 1st course every 30 days after the last day of the previous course of treatment; or give a maintenance dose of 10–15mg/kg per week as a single dose; max: 1g/week. Poor risk patients: see literature for dose adjustments.
Children Dosage:
Not recommended.
Fluorouracil Contraindications:
Poor nutritional state. Depressed bone marrow function. Potentially serious infections.
Fluorouracil Warnings/Precautions:
Narrow margin of safety; monitor for toxicity. Consider hospitalization for 1st course. History of high-dose pelvic irradiation. Previous use of alkylating agents. Widespread involvement of bone marrow by metastatic tumors. Renal or hepatic impairment. Discontinue if signs of toxicity appear (eg, stomatitis, esophagopharyngitis, leukopenia, intractable vomiting, diarrhea, GI ulceration or bleeding, thrombocytopenia, hemorrhage). Monitor WBCs with differential before each dose. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Fluorouracil Classification:
Antimetabolite.
Fluorouracil Interactions:
Potentiated by leucovorin.
Adverse Reactions:
Stomatitis, esophagopharyngitis, GI upset, anorexia, leukopenia, alopecia, dermatitis, hand-foot syndrome; others.
Note:
Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability), DPD (dihydropyrimidine dehydrogenase). Formerly known under the brand name Adrucil.
How Supplied:
Contact supplier.
Colorectal and other GI cancers:
Indications for: Fluorouracil
Palliative management of carcinoma of the colon, rectum, and stomach.
Adult Dosage:
Give by IV inj. 12mg/kg once daily for 4 successive days; max 800mg/day. If no toxicity is observed, 6mg/kg are given on the 6th, 8th, 10th, and 12th days unless toxicity occurs. Maintenance therapy: repeat dosage of 1st course every 30 days after the last day of the previous course of treatment; or give a maintenance dose of 10–15mg/kg per week as a single dose; max: 1g/week. Poor risk patients: see literature for dose adjustments.
Children Dosage:
Not recommended.
Fluorouracil Contraindications:
Poor nutritional state. Depressed bone marrow function. Potentially serious infections.
Fluorouracil Warnings/Precautions:
Narrow margin of safety; monitor for toxicity. Consider hospitalization for 1st course. History of high-dose pelvic irradiation. Previous use of alkylating agents. Widespread involvement of bone marrow by metastatic tumors. Renal or hepatic impairment. Discontinue if signs of toxicity appear (eg, stomatitis, esophagopharyngitis, leukopenia, intractable vomiting, diarrhea, GI ulceration or bleeding, thrombocytopenia, hemorrhage). Monitor WBCs with differential before each dose. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Fluorouracil Classification:
Antimetabolite.
Fluorouracil Interactions:
Potentiated by leucovorin.
Adverse Reactions:
Stomatitis, esophagopharyngitis, GI upset, anorexia, leukopenia, alopecia, dermatitis, hand-foot syndrome; others.
Note:
Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability), DPD (dihydropyrimidine dehydrogenase). Formerly known under the brand name Adrucil.
How Supplied:
Contact supplier.
Pancreatic, thyroid, and other endocrine cancers:
Indications for: Fluorouracil
Palliative management of carcinoma of the pancreas.
Adult Dosage:
Give by IV inj. 12mg/kg once daily for 4 successive days; max 800mg/day. If no toxicity is observed, 6mg/kg are given on the 6th, 8th, 10th, and 12th days unless toxicity occurs. Maintenance therapy: repeat dosage of 1st course every 30 days after the last day of the previous course of treatment; or give a maintenance dose of 10–15mg/kg per week as a single dose; max: 1g/week. Poor risk patients: see literature for dose adjustments.
Children Dosage:
Not recommended.
Fluorouracil Contraindications:
Poor nutritional state. Depressed bone marrow function. Potentially serious infections.
Fluorouracil Warnings/Precautions:
Narrow margin of safety; monitor for toxicity. Consider hospitalization for 1st course. History of high-dose pelvic irradiation. Previous use of alkylating agents. Widespread involvement of bone marrow by metastatic tumors. Renal or hepatic impairment. Discontinue if signs of toxicity appear (eg, stomatitis, esophagopharyngitis, leukopenia, intractable vomiting, diarrhea, GI ulceration or bleeding, thrombocytopenia, hemorrhage). Monitor WBCs with differential before each dose. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Fluorouracil Classification:
Antimetabolite.
Fluorouracil Interactions:
Potentiated by leucovorin.
Adverse Reactions:
Stomatitis, esophagopharyngitis, GI upset, anorexia, leukopenia, alopecia, dermatitis, hand-foot syndrome; others.
Note:
Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability), DPD (dihydropyrimidine dehydrogenase). Formerly known under the brand name Adrucil.
How Supplied:
Contact supplier.
